Loading
Life sciences · Journal article
Journal of Pediatric Endocrinology and Metabolism · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
OBJECTIVES: This study aimed to evaluate the association of baseline body mass index (BMI) status with long-term growth and metabolic outcomes during growth hormone (GH) therapy in children with GH deficiency (GHD). METHODS: From the LG Growth Study, we analyzed 155 children with GHD receiving GH for ≥36 months after age-based propensity score matching (78 elevated-BMI; 77 normal-BMI). Multivariable regression assessed baseline BMI-standard deviation score (SDS) in relation to 36-month changes in height SDS by bone age (BA). Group comparisons assessed longitudinal growth and metabolic outcomes; separate matched obesity and overweight analyses were exploratory. RESULTS: Baseline height SDS by chronological age (CA) did not differ significantly between groups (-2.33 ± 0.58 vs. -2.45 ± 0.65; p=0.1464), whereas height SDS by BA was higher in the elevated-BMI group (0.00 ± 1.68 vs. -0.73 ± 1.28; p=0.0131). Height velocity trajectories were similar (group-by-time p=0.9585). Height SDS by CA improved comparably between groups, whereas ΔHeight SDS by BA differed significantly at 12 months (p=0.0387) and 36 months (p=0.001). Higher baseline BMI-SDS was associated with a lower 36-month change in height SDS by BA in the adjusted model (β=-0.3525; p=0.0216). BMI-SDS decreased in the elevated-BMI group during the first year (p<0.0001), and total cholesterol decreased in both groups. CONCLUSIONS: Higher baseline BMI-SDS was associated with a lower 36-month change in height SDS by BA during GH therapy, while CA-based height gains did not differ significantly between groups.